Adjuvant topical dorzolamide or timolol with intravitreal bevacizumab for diabetic macular edema: A double-blind randomized controlled trial
Diabetic macular edema (DME) is a leading cause of visual impairment among diabetic patients, primarily managed with intravitreal anti-VEGF agents such as bevacizumab. However, the exploration of adjunctive therapies to enhance treatment outcomes remains an area of ongoing research. This study inves...
Uloženo v:
| Hlavní autoři: | , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Caspian Medical Futurology
2024-03-01
|
| Edice: | Journal of Current Biomedical Reports |
| Témata: | |
| On-line přístup: | https://jcbior.com/index.php/JCBioR/article/view/279 |
| Tagy: |
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|